Home > Neurobiological Technologies Inc. NTII

Tag: Neurobiological Technologies Inc. NTII

MondayNov 03, 2008 4:19 am

Neurobiological Technologies, Inc. (NASDAQ: NTII)

Neurobiological Technologies, Inc. (NASDAQ: NTII), a biotechnology company, has their focus on acquiring and developing central nervous system (CNS) related drug candidates. The company strategically in-licenses late-stage CNS agents and then pursues regulatory approval and commercialization. Neurobiological’s goal as a company is to develop and market drug candidates in the United States, Europe and Asia while possibly seeking partnerships with pharmaceutical and biotechnology companies. For further information, visit the Company's web site at www.ntii.com.

Continue Reading

TuesdayOct 14, 2008 4:48 am

Neurobiological Technologies, Inc. (NTII) Moves Up Clinical Trial of Stroke Drug

Neurobiological Technologies, Inc. (NASDAQ: NTII) announced that a recent meeting with the U.S. Food and Drug Administration to discuss a Phase 3 Clinical trial for its Viprinex was encouraging. As a result, the company will consolidate data and patients from its two other trials into a single Phase 3 pivotal trial to be completed by mid-2009. Viprinex is designed to assist with the treatment of acute ischemic stroke. Interim trial results are now expected in January 2009. "Since the two concurrent Phase 3 studies employ the same protocol and patient entry criteria, the validity of the single merged study remains…

Continue Reading

WednesdayJul 23, 2008 5:15 pm

Dutton Associates Featured Company: Neurobiological Technologies, Inc. (NTII)

Neurobiological Technologies, Inc. (NASDAQ: NTII) is a biopharmaceutical company focused on developing innovative and leading agents for central nervous system conditions and other serious medical conditions. The company seeks out drug candidates related to the central nervous system, and develops therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. They employ a strategy of in-licensing late-stage CNS agents and strive to gain regulatory approval and commercialization, either independently or with a strategic partner. Neurobiological Technologies most advanced product candidate is Viprinex™ (ancrod), a drug for treating acute ischemic stroke. The…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .